References
- Scagliotti GV, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–3551.
- Paz-Ares LG, et al. PARAMOUNT: Phase III study of maintenance pemetrexed plus best supported care versus placebo plus BSC immediately following induction treatment with pemetrexed plus cisplatin for advanced NSCLC. ASCO 2011; Abstract CRA7510.
- Johnson DH, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184–2191
- Riely GJ. The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations. Lung Cancer. 2008;60(suppl 2):S19–S22.
- Soda M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–566.
- Takahashi T, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010;17:889–897.
- Crino L, et al. Initial phase II results with crizotinib in advanced ALK-positive non-small-cell lung cancer (NSCLC): PROFILE 1005 (abstract 7514). J Clin Oncol. 2011;29:479s.
- Shaw AT, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harboring ALK gene arrangement: A retrospective analysis. Lancet Oncol. 2011;12:1004–1012.